Total Thrombus-Formation System in Patients with Peripheral Artery Disease

被引:0
作者
Pfrepper, Christian [1 ]
Franke, Careen [1 ]
Metze, Michael [2 ]
Weise, Maria [1 ]
Siegemund, Annelie [1 ,3 ]
Siegemund, Roland [3 ]
Federbusch, Martin [4 ]
Henschler, Reinhard [5 ]
Petros, Sirak [1 ,3 ]
Konert, Manuela [6 ,7 ]
机构
[1] Univ Leipzig, Div Hemostaseol, Med Ctr, Liebigstr 20, D-04103 Leipzig, Germany
[2] Univ Leipzig, Dept Cardiol, Med Ctr, Leipzig, Germany
[3] Univ Leipzig, Med Ctr, Med ICU, Leipzig, Germany
[4] Univ Leipzig, Inst Lab Med, Med Ctr, Leipzig, Germany
[5] Univ Leipzig, Inst Transfus Med, Med Ctr, Leipzig, Germany
[6] Univ Leipzig, Dept Angiol, Med Ctr, Leipzig, Germany
[7] Dr Horst Schmidt Kliniken Wiesbaden, Div Angiol, Wiesbaden, Germany
关键词
antiplatelet monitoring; clopidogrel; dual antiplatelet therapy; peripheral artery disease; T-TAS; FLOW-CHAMBER SYSTEM; CLOPIDOGREL; THROMBOGENICITY; DEFINITION; ASPIRIN;
D O I
10.1177/10760296241301412
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The Total Thrombus-formation Analysis System (T-TAS) is an automated device using coated microchips to assess thrombus formation under flow conditions. Its value to monitor coagulation function in patients under antiplatelet therapy awaits further clarification. This study evaluated T-TAS to detect response to dual antiplatelet therapy (DAPT) in patients with peripheral artery disease (PAD). T-TAS using the platelet-chip (PL-chip) and atheroma-chip (AR-chip) was performed in 60 patients with PAD on the day after lower extremity revascularization. Results were compared with light transmission aggregometry (LTA) and multiple electrode aggregometry (MEA, ADP- and ASPI-test). To determine T-TAS reference ranges, 30 healthy blood donors were enrolled. The area under the curve of the PL-chip (AUC-PL) was outside the reference range in 91.2% and AUC-AR in 21.1% of the PAD patients. Low responders in MEA ASPI, MEA ADP or both tests and low responders in LTA induced by ADP had a significantly higher AUC-PL compared to responders (204 vs 70, p = .016 and 140 vs 32, p < .001), respectively. Median AUC-PL in low responders in LTA and MEA, LTA or MEA and in responders in LTA and MEA was 301, 104 and 32 (p = .001), respectively. Our results suggest that the PL-chip can continuously assess the level of response to DAPT and might be helpful to monitor PAD patients.
引用
收藏
页数:10
相关论文
共 50 条
[31]   Antithrombotic Treatment for Symptomatic Peripheral Artery Disease [J].
Li, Yi-Heng ;
Yeh, Hung-I ;
Hwang, Juey-Jen .
ACTA CARDIOLOGICA SINICA, 2019, 35 (06) :557-562
[32]   Ticagrelor for the prevention of ischemic events in patients with prior myocardial infarction and peripheral artery disease [J].
Nicolau, Jose C. ;
Baracioli, Luciano M. ;
Giugliano, Robert P. .
EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (09) :1013-1019
[33]   Clinical Practice Recommendations for Antithrombotic Management of Peripheral Artery Disease: An Indian Perspective [J].
Pai, Paresh ;
Bedi, Varinder S. ;
Kamerkar, Dhanesh R. ;
George, Robbie ;
Rai, Kumud M. ;
Gupta, P. C. ;
Sekhar, Raghuram ;
Balaji, Venugopal ;
Parakh, Rajiv ;
Subramanian, S. R. ;
Thakore, Vijay ;
Sahu, Tapish ;
Jindal, Ravul .
INDIAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY, 2024, 11 (01) :4-14
[34]   Stroke in Patients With Peripheral Artery Disease: Insights From the EUCLID Study [J].
Kolls, Brad J. ;
Sapp, Shelly ;
Rockhold, Frank W. ;
Jordan, J. Dedrick ;
Dombrowski, Keith E. ;
Fowkes, F. Gerry R. ;
Mahaffey, Kenneth W. ;
Berger, Jeffrey S. ;
Katona, Brian G. ;
Blomster, Juuso I. ;
Norgren, Lars ;
Abramson, Beth L. ;
Leiva-Pons, Jose L. ;
Carlos Prieto, Juan ;
Sokurenko, German ;
Hiatt, William R. ;
Jones, W. Schuyler ;
Patel, Manesh R. .
STROKE, 2019, 50 (06) :1356-1363
[35]   The Influence of Diabetes on Thrombotic Profiles and Outcomes on Patients with Peripheral Artery Disease [J].
Lee, Ivy ;
Agrawal, Aniket ;
Ghandour, Samir ;
Suarez, Sasha ;
Patel, Shiv ;
Young, Elizabeth ;
Hagos, Fanah ;
Yeng, Tina ;
Hall, Ryan ;
Hansraj, Natasha ;
Rodriguez, Adriana ;
Zacharias, Nikolaos ;
Dua, Anahita .
ANNALS OF VASCULAR SURGERY, 2025, 110 :246-259
[36]   Cilostazol decreases total atrial conduction time in patients with peripheral artery disease [J].
Alizade, E. ;
Sahin, M. ;
Simsek, Z. ;
Acar, G. ;
Bulut, M. ;
Guler, A. ;
Avci, A. ;
Kalkan, M. E. ;
Pala, S. ;
Akcakoyun, M. ;
Esen, A. M. .
PERFUSION-UK, 2014, 29 (03) :265-271
[37]   Mono or Dual Antiplatelet Therapy for Treating Patients with Peripheral Artery Disease after Lower Extremity Revascularization: A Systematic Review and Meta-Analysis [J].
Tsai, Shang-Yu ;
Li, Ying-Sheng ;
Lee, Che-Hsiung ;
Cha, Shion-Wei ;
Wang, Yao-Chang ;
Su, Ta-Wei ;
Yu, Sheng-Yueh ;
Yeh, Chi-Hsiao .
PHARMACEUTICALS, 2022, 15 (05)
[38]   Synergistic influence of rivaroxaban on inflammation and coagulation biomarkers in patients with coronary artery disease and peripheral artery disease on aspirin therapy [J].
Tantry, Udaya ;
Cummings, Charles ;
Mackrell, Peter ;
Gonze, Mark ;
Ulloa, Kristian ;
Bafford, Richard ;
Rout, Amit ;
Sukhi, Ajaypaul ;
Gurbel, Paul .
FUTURE CARDIOLOGY, 2020, 16 (02) :69-75
[39]   Differences in responses of platelets to fluid shear stress in patients with peripheral artery disease (PAD) and coronary artery disease (CAD) [J].
Nambi, Vijay ;
Kimball, Kay T. ;
Bray, Paul F. ;
Bergeron, Angela L. ;
Johnson, Shawna L. ;
Morrisett, Joel D. ;
Chen, Changyi ;
Lin, Peter H. ;
Lumsden, Alan B. ;
Ballantyne, Christie M. ;
Dong, Jing-Fei .
PLATELETS, 2009, 20 (03) :199-205
[40]   Antithrombotic strategies for patients with coronary and lower extremity peripheral artery diseases: a narrative review [J].
De Luca, Leonardo ;
Bonaca, Marc P. ;
Magnani, Giulia .
EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2020, 18 (12) :881-889